Vasodilator Effects of Ibudilast on Retinal Blood Vessels in Anesthetized Rats

Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-α]pyridine) is clinically used as a cerebral vasodilator in Japan. However, the effects of ibudilast on retinal blood vessels have not been fully examined. The aim of this study, therefore, was to examine the effects of ibudilast on retinal blood vesse...

Full description

Saved in:
Bibliographic Details
Published inBiological & Pharmaceutical Bullein Vol. 32; no. 11; pp. 1924 - 1927
Main Authors Noguchi, Masahiro, Mori, Asami, Sakamoto, Kenji, Nakahara, Tsutomu, Ishii, Kunio
Format Journal Article
LanguageEnglish
Japanese
Published Japan The Pharmaceutical Society of Japan 01.11.2009
Pharmaceutical Society of Japan
Japan Science and Technology Agency
Subjects
Anesthesia
Animals
cyclooxygenase
ibudilast
Male
prostanoid
Pyridines - pharmacology
Rats
Rats, Wistar
retinal blood vessel
Retinal Vessels - drug effects
Vasodilator Agents - pharmacology
Online AccessGet full text

Cover

Abstract Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-α]pyridine) is clinically used as a cerebral vasodilator in Japan. However, the effects of ibudilast on retinal blood vessels have not been fully examined. The aim of this study, therefore, was to examine the effects of ibudilast on retinal blood vessels in rats in vivo. Male Wistar rats (8 to 10 weeks old) were anesthetized with thiobutabarbital (120 mg/kg, intraperitoneally (i.p.)). Retinal vascular images were captured with a fundus camera system for small animals, and the diameter of retinal blood vessels was measured. Ibudilast (0.1 and 1 mg/kg, intravenously (i.v.)) elicited a sustained increase in the diameter of retinal blood vessels and heart rate without altering systemic blood pressure. The effects of ibudilast were significantly reduced by treatment with the nonselective cyclooxygenase inhibitor indomethacin (5 mg/kg, i.p.). These results suggest that ibudilast dilates retinal blood vessels through cyclooxygenase-dependent mechanisms in rats in vivo.
AbstractList Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-α]pyridine) is clinically used as a cerebral vasodilator in Japan. However, the effects of ibudilast on retinal blood vessels have not been fully examined. The aim of this study, therefore, was to examine the effects of ibudilast on retinal blood vessels in rats in vivo. Male Wistar rats (8 to 10 weeks old) were anesthetized with thiobutabarbital (120 mg/kg, intraperitoneally (i.p.)). Retinal vascular images were captured with a fundus camera system for small animals, and the diameter of retinal blood vessels was measured. Ibudilast (0.1 and 1 mg/kg, intravenously (i.v.)) elicited a sustained increase in the diameter of retinal blood vessels and heart rate without altering systemic blood pressure. The effects of ibudilast were significantly reduced by treatment with the nonselective cyclooxygenase inhibitor indomethacin (5 mg/kg, i.p.). These results suggest that ibudilast dilates retinal blood vessels through cyclooxygenase-dependent mechanisms in rats in vivo.
Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-alpha]pyridine) is clinically used as a cerebral vasodilator in Japan. However, the effects of ibudilast on retinal blood vessels have not been fully examined. The aim of this study, therefore, was to examine the effects of ibudilast on retinal blood vessels in rats in vivo. Male Wistar rats (8 to 10 weeks old) were anesthetized with thiobutabarbital (120 mg/kg, intraperitoneally (i.p.)). Retinal vascular images were captured with a fundus camera system for small animals, and the diameter of retinal blood vessels was measured. Ibudilast (0.1 and 1 mg/kg, intravenously (i.v.)) elicited a sustained increase in the diameter of retinal blood vessels and heart rate without altering systemic blood pressure. The effects of ibudilast were significantly reduced by treatment with the nonselective cyclooxygenase inhibitor indomethacin (5 mg/kg, i.p.). These results suggest that ibudilast dilates retinal blood vessels through cyclooxygenase-dependent mechanisms in rats in vivo.
Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-α]pyridine) is clinically used as a cerebral vasodilator in Japan. However, the effects of ibudilast on retinal blood vessels have not been fully examined. The aim of this study, therefore, was to examine the effects of ibudilast on renal blood vessels in rats in vivo. Male Wistar rats (8 to 10 weeks old) were anesthetized with thiobutabarbital (120 mg/kg, intraperitoneally (i.p.)). Retinal vascular images were captured with a fundus camera system for small animals, and the diameter of retinal blood vessels was measured. Ibudilast (0.1 and 1 mg/kg, intravenously (i.v.)) elicited a sustained increase in the diameter of retinal blood vessels and heart rate without altering systemic blood pressure. The effects of ibudilast were significantly reduced by treatment with the nonselective cyclooxygenase inhibitor indomethacin (5 mg/kg, i.p.). These results suggest that ibudilast dilates retinal blood vessels through cyclooxygenase-dependent mechanisms in rats in vivo.
Author Noguchi, Masahiro
Mori, Asami
Sakamoto, Kenji
Ishii, Kunio
Nakahara, Tsutomu
Author_xml – sequence: 1
  fullname: Noguchi, Masahiro
  organization: Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences
– sequence: 2
  fullname: Mori, Asami
  organization: Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences
– sequence: 3
  fullname: Sakamoto, Kenji
  organization: Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences
– sequence: 4
  fullname: Nakahara, Tsutomu
  organization: Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences
– sequence: 5
  fullname: Ishii, Kunio
  organization: Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19881310$$D View this record in MEDLINE/PubMed
BookMark eNp9kcFrFDEUxoNU7LZ68i4BQQ8ya16SmUyObWltoSgU7TUkmTd2lmyyTmYO9q9vtru20IOXF8j3y_e-l3dEDmKKSMh7YEvgsv3qNm4p-BI0l6_IAoRUVc2hPiALpqGtGqjbQ3KU84oxphgXb8gh6LYFAWxBvt_anLoh2CmN9Lzv0U-Zpp5euXl7myeaIr3BaYg20NOQUkdvMWcMmQ6RnkTM011R77GjN3bKb8nr3oaM7_bnMfl1cf7z7LK6_vHt6uzkuvKKi6nCBqVtbEnvQTeWKdHq3jnwtde2lk77Tna1RHRaqN7qtrFdU6OQXCiuvBPH5PPOdzOmP3MJYdZD9hiCjZjmbJSQAEpCXchP_yU5CN5yUAX8-AJcpXksY2cDUpYctWJQqC87yo8p5xF7sxmHtR3_GmBmuw5T1mEEN9t1FPrD3nN2a-ye2f3_F-BiBxR18DakGIaIz519Vm5IIRnOmDaMCQ5gGIdH-21RsmmYborR6c5olSf7G5862XEafMCnVLCvj-__if7OjgajeABo5rOZ
CitedBy_id crossref_primary_10_1248_bpb_33_844
crossref_primary_10_18500_1816_9775_2018_18_1_71_78
crossref_primary_10_1016_j_nbd_2016_05_002
crossref_primary_10_1248_bpb_32_2068
crossref_primary_10_1093_brain_awac136
crossref_primary_10_1248_yakushi_13_00228_2
crossref_primary_10_1254_fpj_135_146
Cites_doi 10.1001/archopht.116.11.1491
10.1007/s001250051171
10.1097/01.icu.0000156134.38495.0b
10.1159/000267168
10.1016/S1350-9462(02)00008-3
10.1111/j.1748-1716.1990.tb08993.x
10.1161/01.RES.83.7.714
10.1080/01616412.1993.11740130
10.1016/S0014-2999(98)00015-6
10.1097/00004647-199702000-00011
10.1007/s00210-007-0165-7
10.1159/000055622
10.1016/j.cellsig.2007.03.012
10.1016/j.ejphar.2006.02.053
10.1016/j.ejphar.2008.10.060
10.1016/0306-3623(86)90050-9
10.1111/j.1476-5381.1991.tb12457.x
10.1254/jjp.33.267
10.1097/00005344-198500071-00018
10.1254/jjp.33.1215
10.1016/j.ejphar.2007.05.052
10.1002/dmrr.432
10.1111/j.1748-1716.1991.tb09130.x
10.1016/0014-4835(91)90059-N
10.1111/j.1476-5381.1994.tb14855.x
10.1152/physrev.1975.55.3.383
ContentType Journal Article
Copyright 2009 The Pharmaceutical Society of Japan
Copyright Japan Science and Technology Agency 2009
Copyright_xml – notice: 2009 The Pharmaceutical Society of Japan
– notice: Copyright Japan Science and Technology Agency 2009
CorporateAuthor Department of Molecular Pharmacology
Kitasato University School of Pharmaceutical Sciences
CorporateAuthor_xml – name: Department of Molecular Pharmacology
– name: Kitasato University School of Pharmaceutical Sciences
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7QR
7TK
7U9
8FD
FR3
H94
P64
7X8
DOI 10.1248/bpb.32.1924
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList Virology and AIDS Abstracts

MEDLINE
MEDLINE - Academic
Neurosciences Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1347-5215
EndPage 1927
ExternalDocumentID 3121465751
10_1248_bpb_32_1924
19881310
cs7biolo_2009_003211_021_1924_1927466096
article_bpb_32_11_32_11_1924_article_char_en
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
1CY
23N
2WC
53G
5GY
6J9
ABTAH
ACGFO
ACIWK
ACPRK
ADBBV
AENEX
AFFNX
AFRAH
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKOMP
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
HH5
JMI
JSF
JSH
KQ8
MOJWN
OK1
P2P
RJT
RZJ
TR2
VH1
XSB
ZY4
.55
ABJNI
TKC
X7M
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7QR
7TK
7U9
8FD
FR3
H94
P64
7X8
ID FETCH-LOGICAL-c723t-e6e4a6a248c196a07389fbb1c5c9a54b9cd4d54eeb937fa986ad65e3423727cb3
ISSN 0918-6158
IngestDate Fri Apr 12 09:16:58 EDT 2024
Fri Apr 12 03:48:32 EDT 2024
Thu Oct 10 19:47:10 EDT 2024
Fri Aug 23 01:02:49 EDT 2024
Thu May 23 23:51:11 EDT 2024
Fri May 31 15:04:09 EDT 2024
Thu Aug 17 20:28:23 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c723t-e6e4a6a248c196a07389fbb1c5c9a54b9cd4d54eeb937fa986ad65e3423727cb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/bpb/32/11/32_11_1924/_article/-char/en
PMID 19881310
PQID 1449375701
PQPubID 1966364
PageCount 4
ParticipantIDs proquest_miscellaneous_734117415
proquest_miscellaneous_21328217
proquest_journals_1449375701
crossref_primary_10_1248_bpb_32_1924
pubmed_primary_19881310
medicalonline_journals_cs7biolo_2009_003211_021_1924_1927466096
jstage_primary_article_bpb_32_11_32_11_1924_article_char_en
PublicationCentury 2000
PublicationDate 2009-11-01
PublicationDateYYYYMMDD 2009-11-01
PublicationDate_xml – month: 11
  year: 2009
  text: 2009-11-01
  day: 01
PublicationDecade 2000
PublicationPlace Japan
PublicationPlace_xml – name: Japan
– name: Tokyo
PublicationTitle Biological & Pharmaceutical Bullein
PublicationTitleAlternate Biol Pharm Bull
PublicationYear 2009
Publisher The Pharmaceutical Society of Japan
Pharmaceutical Society of Japan
Japan Science and Technology Agency
Publisher_xml – name: The Pharmaceutical Society of Japan
– name: Pharmaceutical Society of Japan
– name: Japan Science and Technology Agency
References 33) Willette R. N., Shiloh A. O., Sauermelch C. F., Sulpizio A., Michell M. P., Cieslinski L. B., Torphy T. J., Ohlstein E. H., J. Cereb. Blood Flow Metab., 17, 210—219 (1997).
25) Ogawa N., Saito M., Mori A., Sakamoto K., Kametaka S., Nakahara T., Ishii K., Naunyn-Schmiedeberg's Arch. Pharmacol., 375, 323—328 (2007).
31) Komas N., Lugnier C., Stoclet J. C., Br. J. Pharmacol., 104, 495—503 (1991).
20) Fukuyama H., Kimura J., Yamaguchi S., Yamauchi H., Ogawa M., Doi T., Yonekura Y., Konishi J., Neurol. Res., 15, 169—173 (1993).
29) Lindgren S. H., Andersson T. L., Vinge E., Andersson K. E., Acta Physiol. Scand., 140, 209—219 (1990).
8) Boussery K., Delaey C., Van de Voorde J., Invest. Ophthalmol. Vis. Sci., 43, 3279—3286 (2002).
13) Nagai H., Iwamoto T., Nishiyori T., Takizawa T., Tsuchiya H., Koda A., Jpn. J. Pharmacol., 33, 1215—1223 (1983).
17) Kudo Y., Sugiura H., Ohashi M., Nishino K., Gen. Pharmacol., 17, 339—341 (1986).
5) Delaey C., Van De Voorde J., Ophthalmic Res., 32, 249—256 (2000).
10) Bill A., Nilsson S. F., J. Cardiovasc. Pharmacol., 7 (Suppl. 3), S96—S102 (1985).
16) Kishi Y., Ohta S., Kasuya N., Sakita S., Ashikaga T., Isobe M., Drug Rev., 19, 215—225 (2001).
1) Schmetterer L., Wolzt M., Diabetologia, 42, 387—405 (1999).
26) Hotta H., Ito H., Kagitani F., Sato A., Eur. J. Pharmacol., 344, 49—52 (1998).
14) Nishino K., Ohkubo H., Ohashi M., Hara S., Kito J., Irikura T., Jpn. J. Pharmacol., 33, 267—278 (1983).
4) Grieshaber M. C., Flammer J., Curr. Opin. Ophthalmol., 16, 79—83 (2005).
15) Ohashi M., Kito J., Nishino K., Arch. Int. Pharmacodyn. Ther., 280, 216—229 (1986).
11) Harris A., Ciulla T. A., Chung H. S., Martin B., Arch. Ophthalmol., 116, 1491—1495 (1998).
6) Benedito S., Prieto D., Nielsen P. J., Nyborg N. C., Exp. Eye Res., 52, 575—579 (1991).
9) Delaey C., Van de Voorde J., Circ. Res., 83, 714—720 (1998).
12) Bill A., Physiol. Rev., 55, 383—417 (1975).
22) Gibson L. C., Hastings S. F., McPhee I., Clayton R. A., Darroch C. E., Mackenzie A., Mackenzie F. L., Nagasawa M., Stevens P. A., Mackenzie S. J., Eur. J. Pharmacol., 538, 39—42 (2006).
27) Miwa T., Mori A., Nakahara T., Ishii K., Eur. J. Pharmacol., 602, 112—116 (2009).
3) Flammer J., Orgül S., Costa V. P., Orzalesi N., Krieglstein G. K., Serra L. M., Renard J. P., Stefánsson E., Prog. Retin. Eye Res., 21, 359—393 (2002).
18) Armstead W. M., Mirro R., Leffler C. W., Busija D. W., J. Pharmacol. Exp. Ther., 244, 138—143 (1988).
23) Suzuki R., Sugihara I., Ishibashi T., Kurimoto S., Ophthalmic Res., 24, 197—202 (1992).
24) Mori A., Saito M., Sakamoto K., Narita M., Nakahara T., Ishii K., Eur. J. Pharmacol., 570, 135—141 (2007).
2) De La Cruz J. P., González-Correa J. A., Guerrero A., de la Cuesta F. S., Diabetes Metab. Res. Rev., 20, 91—113 (2004).
21) Souness J. E., Villamil M. E., Scott L. C., Tomkinson A., Giembycz M. A., Raeburn D., Br. J. Pharmacol., 111, 1081—1088 (1994).
19) Izumi Y., Gotoh F., Fukuuchi Y., Hata T., Imai A., Isozumi K., Arzneimittelforschung, 40, 1300—1303 (1990).
30) Lindgren S., Andersson K. E., Acta Physiol. Scand., 142, 77—82 (1991).
32) Heaslip R. J., Buckley S. K., Sickels B. D., Grimes D., J. Pharmacol. Exp. Ther., 257, 741—747 (1991).
7) Haefliger I. O., Flammer J., Luscher T. F., Invest. Ophthalmol. Vis. Sci., 33, 2340—2343 (1992).
28) Sun B., Li H., Shakur Y., Hensley J., Hockman S., Kambayashi J., Manganiello V. C., Liu Y., Cell Signal., 19, 1765—1771 (2007).
22
25
26
Miwa T., Mori A., Nakahara T., Ishi (27) 2009; 602
Boussery K., Delaey C., Van de Voor (8) 2002; 43
Mori A., Saito M., Sakamoto K., Nar (24) 2007; 570
Bill A. (12) 1975; 55
Suzuki R., Sugihara I., Ishibashi T (23) 1992; 24
(21) 1994; 111
Haefliger I. O., Flammer J., Lusche (7) 1992; 33
Delaey C., Van De Voorde J. (5) 2000; 32
10
33
Delaey C., Van de Voorde J. (9) 1998; 83
13
(18) 1988; 244
Lindgren S. H., Andersson T. L., Vi (29) 1990; 140
14
Fukuyama H., Kimura J., Yamaguchi S (20) 1993; 15
17
Sun B., Li H., Shakur Y., Hensley J (28) 2007; 19
Harris A., Ciulla T. A., Chung H. S (11) 1998; 116
(31) 1991; 104
(19) 1990; 40
1
2
Kishi Y., Ohta S., Kasuya N., Sakit (16) 2001; 19
3
4
6
Lindgren S., Andersson K. E. (30) 1991; 142
Ohashi M., Kito J., Nishino K. (15) 1986; 280
(32) 1991; 257
References_xml – volume: 33
  start-page: 2340
  issn: 0146-0404
  year: 1992
  ident: 7
  publication-title: Invest. Ophthalmol. Vis. Sci.
  contributor:
    fullname: Haefliger I. O., Flammer J., Lusche
– volume: 116
  start-page: 1491
  year: 1998
  ident: 11
  publication-title: Arch. Ophthalmol.
  doi: 10.1001/archopht.116.11.1491
  contributor:
    fullname: Harris A., Ciulla T. A., Chung H. S
– ident: 1
  doi: 10.1007/s001250051171
– ident: 4
  doi: 10.1097/01.icu.0000156134.38495.0b
– volume: 24
  start-page: 197
  issn: 0030-3747
  year: 1992
  ident: 23
  publication-title: Ophthalmic Res.
  doi: 10.1159/000267168
  contributor:
    fullname: Suzuki R., Sugihara I., Ishibashi T
– ident: 3
  doi: 10.1016/S1350-9462(02)00008-3
– volume: 140
  start-page: 209
  year: 1990
  ident: 29
  publication-title: Acta Physiol. Scand.
  doi: 10.1111/j.1748-1716.1990.tb08993.x
  contributor:
    fullname: Lindgren S. H., Andersson T. L., Vi
– volume: 83
  start-page: 714
  issn: 0009-7330
  year: 1998
  ident: 9
  publication-title: Circ. Res.
  doi: 10.1161/01.RES.83.7.714
  contributor:
    fullname: Delaey C., Van de Voorde J.
– volume: 19
  start-page: 215
  year: 2001
  ident: 16
  publication-title: Drug Rev.
  contributor:
    fullname: Kishi Y., Ohta S., Kasuya N., Sakit
– volume: 15
  start-page: 169
  issn: 0161-6412
  year: 1993
  ident: 20
  publication-title: Neurol. Res.
  doi: 10.1080/01616412.1993.11740130
  contributor:
    fullname: Fukuyama H., Kimura J., Yamaguchi S
– ident: 26
  doi: 10.1016/S0014-2999(98)00015-6
– volume: 257
  start-page: 741
  issn: 0022-3565
  issue: 2
  year: 1991
  ident: 32
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 40
  start-page: 1300
  issn: 0004-4172
  issue: 12
  year: 1990
  ident: 19
  publication-title: Arzneimittelforschung
– ident: 33
  doi: 10.1097/00004647-199702000-00011
– ident: 25
  doi: 10.1007/s00210-007-0165-7
– volume: 32
  start-page: 249
  issn: 0030-3747
  year: 2000
  ident: 5
  publication-title: Ophthalmic Res.
  doi: 10.1159/000055622
  contributor:
    fullname: Delaey C., Van De Voorde J.
– volume: 19
  start-page: 1765
  issn: 0898-6568
  year: 2007
  ident: 28
  publication-title: Cell Signal.
  doi: 10.1016/j.cellsig.2007.03.012
  contributor:
    fullname: Sun B., Li H., Shakur Y., Hensley J
– ident: 22
  doi: 10.1016/j.ejphar.2006.02.053
– volume: 602
  start-page: 112
  issn: 0014-2999
  year: 2009
  ident: 27
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2008.10.060
  contributor:
    fullname: Miwa T., Mori A., Nakahara T., Ishi
– ident: 17
  doi: 10.1016/0306-3623(86)90050-9
– volume: 104
  start-page: 495
  issn: 0007-1188
  issue: 2
  year: 1991
  ident: 31
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/j.1476-5381.1991.tb12457.x
– ident: 14
  doi: 10.1254/jjp.33.267
– ident: 10
  doi: 10.1097/00005344-198500071-00018
– volume: 244
  start-page: 138
  issn: 0022-3565
  issue: 1
  year: 1988
  ident: 18
  publication-title: J. Pharmacol. Exp. Ther.
– ident: 13
  doi: 10.1254/jjp.33.1215
– volume: 570
  start-page: 135
  issn: 0014-2999
  year: 2007
  ident: 24
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2007.05.052
  contributor:
    fullname: Mori A., Saito M., Sakamoto K., Nar
– volume: 280
  start-page: 216
  year: 1986
  ident: 15
  publication-title: Arch. Int. Pharmacodyn. Ther.
  contributor:
    fullname: Ohashi M., Kito J., Nishino K.
– ident: 2
  doi: 10.1002/dmrr.432
– volume: 142
  start-page: 77
  year: 1991
  ident: 30
  publication-title: Acta Physiol. Scand.
  doi: 10.1111/j.1748-1716.1991.tb09130.x
  contributor:
    fullname: Lindgren S., Andersson K. E.
– volume: 43
  start-page: 3279
  issn: 0146-0404
  year: 2002
  ident: 8
  publication-title: Invest. Ophthalmol. Vis. Sci.
  contributor:
    fullname: Boussery K., Delaey C., Van de Voor
– ident: 6
  doi: 10.1016/0014-4835(91)90059-N
– volume: 111
  start-page: 1081
  issn: 0007-1188
  issue: 4
  year: 1994
  ident: 21
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/j.1476-5381.1994.tb14855.x
– volume: 55
  start-page: 383
  issn: 0031-9333
  year: 1975
  ident: 12
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.1975.55.3.383
  contributor:
    fullname: Bill A.
SSID ssj0007023
ssib023156946
ssib002483627
ssib002822050
ssib017383521
Score 1.9798088
Snippet Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-α]pyridine) is clinically used as a cerebral vasodilator in Japan. However, the effects of ibudilast on retinal...
Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-alpha]pyridine) is clinically used as a cerebral vasodilator in Japan. However, the effects of ibudilast on...
SourceID proquest
crossref
pubmed
medicalonline
jstage
SourceType Aggregation Database
Index Database
Publisher
StartPage 1924
SubjectTerms Anesthesia
Animals
cyclooxygenase
ibudilast
Male
prostanoid
Pyridines - pharmacology
Rats
Rats, Wistar
retinal blood vessel
Retinal Vessels - drug effects
Vasodilator Agents - pharmacology
Title Vasodilator Effects of Ibudilast on Retinal Blood Vessels in Anesthetized Rats
URI https://www.jstage.jst.go.jp/article/bpb/32/11/32_11_1924/_article/-char/en
http://mol.medicalonline.jp/library/journal/download?GoodsID=cs7biolo/2009/003211/021&name=1924-1927e
https://www.ncbi.nlm.nih.gov/pubmed/19881310
https://www.proquest.com/docview/1449375701
https://search.proquest.com/docview/21328217
https://search.proquest.com/docview/734117415
Volume 32
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Biological and Pharmaceutical Bulletin, 2009/11/01, Vol.32(11), pp.1924-1927
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKQAIJIej4CAzww7SXLaVxnA-LB1SmoYFEhaZu2lvkpC7LWJNqSR66P4G_mrs4dVLUSYOXqI19rur75XJn3_1MyK7wYz7jobJDyYXNvUDZchomtq8ER9pJxhSuQ34f-8en_Nu5d97r_e5kLVVlPEhuNtaV_I9W4R7oFatk_0GzZlC4AZ9Bv3AFDcP1Tjo-k0U-Ta8wbt4_ahMzvsYV3i1K3Ak4wZpm0MNnzFDfP0Oq8Ks6B3YERg68vzK9AZ_zRGpGJ7O_mxqjiNhYXKytfMddzu46P_Ynnqmia38KeZFe50aRuS5lHxVynprlHPlLAkTypjDo0jSMoQEZpGsUFVWZz6u1ZQnR1Od11hedEOJSzcs-UNq6ujyAyFfXb67Mb7u8Wa1KUBpjirFh58UMX4ONRp9xLGSIF_HAZYNWqEut_dcrzyQiYggE4hEIRy6LUPgeuc_AaIW1kW9DqWBYHxVo_lZT6wnCHzq_vObdPLgEBx-ZGx7P9aabJj-5PZapfZrJU_KkCUboSCPrGemprE-2RxkAar6ke7ROD673Xfrk4eHqaMA-2fuh8bA8oJO2fq84qEUMFfpym4w7CKUNQmk-owahNM9og1BaI5Q2CKVpRrsIpYjQ5-T0y9Hk8NhuTvCwk4C5pa18xaUvYZISsPQSXiehmMWxk3iJkB6PRTLlU48rFYOXPJMi9OXU9xSyUoJfncTuC7KV5Zl6RWjih3KmxCzEKGQaJAJPYmAwPvhgDmPSIrurmY8Wmqgl2qBdi3zUWjGdmqfXdHKaK_Y2jVgCCRbHIp_WVBk1xqCIkiKoWdPwWFeBhLsMhgD_WQ-D0OW-PxS-RXZWym-FHc7h_3vB0LHIe9MMOsXNO5mpvCoi5rgsZE5gEXpLjwAcUgcDBIu81KhqJ0KEoQOB3Ou7TdIb8qh9pHfIVnldqbfge5fxu_qh-AMdYNlG
link.rule.ids 315,783,787,27938,27939
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vasodilator+Effects+of+Ibudilast+on+Retinal+Blood+Vessels+in+Anesthetized+Rats&rft.jtitle=Biological+%26+pharmaceutical+bulletin&rft.au=Noguchi%2C+Masahiro&rft.au=Mori%2C+Asami&rft.au=Sakamoto%2C+Kenji&rft.au=Nakahara%2C+Tsutomu&rft.date=2009-11-01&rft.issn=0918-6158&rft.eissn=1347-5215&rft.volume=32&rft.issue=11&rft.spage=1924&rft.epage=1927&rft_id=info:doi/10.1248%2Fbpb.32.1924&rft.externalDBID=n%2Fa&rft.externalDocID=10_1248_bpb_32_1924
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-6158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-6158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-6158&client=summon